Leading SMEs of India 2022

19 Experts' View Leading SMEs of India 2022 How would you describe the journey of your company since its inception? What are some of the key milestones of the company in recent years? Changing RV Lifesciences from a pure play Contract Manufacturing Organization to a hybrid organization focused on both own products and contract manufacturing have been the biggest challenges so far. Acquired by RV Group (headquartered out of Singapore) in 2017, the manufacturing facility and R & D centre is set to play a pivotal role in entry into EU and other regulated markets apart from Rest of the World (RoW). We have set-up a full fledged R & D centre manned by over 30 scientists to be able to deliver on our Group credo of bringing innovative medicines at an affordable price to the patients across the globe. Our therapeutic categories span Cardiology, Diabetology, Antivirals, RV Lifesciences Limited Rajesh Kumar Managing Director Anti-infectives, Hepatology, Antigout, Pain management and others. We have substantially upgraded our manufacturing facility to obtain EU certification. Apart from EU we have Malaysian PIC/s, Russian, Uzbekistan and Tanzania accreditation. We have also given especial focus to the Environmental, Health and Safety norms to comply with ISO 9001-2015, ISO 14001-2015, ISO 45001-2018. What are some of the key factors that differentiates your company from its peers? / What are the factors that give you an edge over your peers? RV Group has a unique position in the South East Asian (SEA) pharmaceutical landscape, as one of the foremost Indian companies with strong presence in Vietnam (2 manufacturing facilities), Myanmar (1 manufacturing facility), Cambodia, Philippines, Malaysia and Thailand. Apart from SEA we have presence in India (1 manufacturing facility) and CIS (1 manufacturing facility in Kazakhstan). Our products are exported to over 20 countries currently which is set to increase to over 50 in the next 2 years. Given the strong front end presence in SEA combined with R & D and manufacturing excellence bookended by a strong management team we believe that we have a unique pharma story compared to any other pharma company in India. We are now set to further our presence in Regulated and other RoW markets. Our unique cultural values of Focus, Fast, Flexible and Forward looking which each and every employee embodies, together with a quality mindset is set to take RV Group to greater heights. What is your outlook on the pharmaceutical sector in India? What is your company’s growth strategy for next 3-5 years? The Indian pharma industry is expected to grow to $130 billion by 2030 and become the leading provider of medicines to the world. The Indian pharma industry is currently valued at $49 billion and is the third largest in the world. India is the pill factory to the world supplying close to 35% of the world’s requirements. The challenges for the India pharma sector is to scale up Biosimilars to a World Class level as well as to enter the Discovery space. Both have inherent challenges of having a long term vision with investment and balancing the short term cash flows to fund the long term. Maximum revenues in the pharma space lies in Patented products and Biologics both of which require significant investment and a disciplinedmindset. By 2030, RV Group’s target is to become the biggest pharmaceutical company in South east Asia and to achieve $500 million revenue worldwide. The pillars of success will be identifying and developing products which serve the unmet needs of the population especially at an affordable price in a sustainable manner. Dun & Bradstreet